3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
16
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Colorectal Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Malignancies
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Hypertension, Portal
1
Hepato Cellular Carcinoma
1
Hematologic Neoplasms
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
5
Nivolumab
5
selpercatinib
4
Iodine-124
4
Biopsy
4
binimetinib
3
Iodine-131
3
Cetuximab
3
ulixertinib
2
trametinib
2
pembrolizumab
2
omipalisib
2
larotrectinib
2
defactinib
2
dabrafenib
2
Surveys and Questionnaires
2
Sunitinib
2
Radiosurgery
2
Ipilimumab
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tipifarnib
1
temsirolimus
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
tremelimumab
×
90 days
×
Clear all
No trials found.